The goal of this clinical trial is to learn if troxerutin works to prevent thrombotic events in mild or severe COVID-19 patients. It will also learn about the safety of troxerutin. The main questions it aims to answer are:
* Does troxerutin lower the number of thrombotic events in participants? * What medical problems do participants have when taking troxerutin? Researchers will compare troxerutin to a placebo (a look-alike substance that contains no drug) to see if troxerutin works to prevent thrombotic events in COVID-19 patients.
Participants will:
* Take troxerutin or a placebo every day for 7 days. * Visit the clinic at the first, fourth, seventh and 28th days after enrollment for checkups and tests * Keep a diary of their symptoms and the number of times of thrombotic events, bleeding events and type II HIT-related thrombocytopenia
Respiratory rate ≥30 breaths/min
Severe respiratory distress
Oxygen saturation (SpO₂) ≤90% in room air
Progressive deterioration of clinical symptoms with lung imaging showing significant progression of lesions (>50%) within 24 to 48 hours.
Pregnant or lactating women.
Postpartum (within 6 weeks).
Extreme weight (100 kilograms).
Clinical need for heparin therapy.
Westlake University
Lead sponsor
Shaoxing Central Hospital
Collaborator
Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University
Collaborator